Hot Investor Mandate 3: Hong Kong Conglomerate Invests in Brain Diseases, Oncology and Ophthalmology

9 Mar

A multi-disciplinary conglomerate based in Hong Kong continues to diversify its business and growth globally with interests in a diverse range of business partnerships, including life sciences. The for, can and typically takes a long-term approach to such investments, with a focus on early stage life science companies, and syndicates with prominent co-investors to form a global network for sourcing and accessing deals, where the allocation size can be flexible depending on the deal. The firm is actively seeking new opportunities based in the U.S. and China.

Within healthcare, the firm looks at cutting-edge biotech therapeutic technologies across small molecule, biologics, and novel therapies. The group focuses on brain diseases, oncology, and ophthalmology. The group is also interested in drug delivery platforms and genomic diagnostics. In terms of development stages, the group focuses on preclinical to early clinical stage assets that are seeking series A or B financing.

The firm looks for experienced and competent teams with sector expertise and track record of success. The firm prefers opportunities where they have already identified a healthcare-focused lead investor. The firm typically requests board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: